Here is a nice summary of a report published in Jan of 2019 by CMR International and published in Nature Reviews... Core finding - Most clinical candidates die in the early phases. But companies seem to be getting smarter and are increasing their success rate. The review gives several potential explanations for this.
PhI may still be a killing field of failure but PhIII success rates have surged, signaling tectonic shifts in biopharma R&D
This is a really nice summary about the conclusions in the review. Also the graphs are interactive and pretty.
Is it surprising that clinical trials are hard? Not really. Is it surprising that companies are getting more willing to pull the plug despite heavy up-front investment? Not really.
No comments:
Post a Comment